0000000001316876

AUTHOR

Andrea Mari

showing 9 related works from this author

Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy f…

2020

Background: A marker of urothelial damage could be helpful for early detection and monitoring of local toxicity due to intravesical therapy for non-muscle invasive bladder cancer (NMIBC). The aim of the study was to investigate the correlation between fibronectin (FN) gene expression in bladder washings and local toxicity secondary to adjuvant intravesical therapy. Materials and methods: Patients undergoing adjuvant intravesical therapy for NMIBC and age-matched healthy patients were enrolled. Real time polymerase chain reaction was performed to analyze FN expression in bladder washings. Local toxicity was classified as: 0–1 mild (no medical therapy), 2 moderate (medical therapy and/or inst…

Urologymedicine.medical_treatment030232 urology & nephrologyEarly detectionBacillus Calmette–Guerinlcsh:RC870-92303 medical and health sciences0302 clinical medicinefibronectinnon-muscle invasive bladder cancerGene expressionbladder washingMedicineBladder cancerbiologybusiness.industrytoxicitylcsh:Diseases of the genitourinary system. Urologymedicine.diseaseFibronectin030220 oncology & carcinogenesisToxicitybiology.proteinCancer researchBiomarker (medicine)biomarkerOriginal ArticlebusinessNon muscle invasiveAdjuvantTherapeutic advances in urology
researchProduct

Prediction of significant renal function decline after open, laparoscopic, and robotic partial nephrectomy: External validation of the Martini’s nomo…

2022

Objectives: Martini et al. developed a nomogram to predict significant (>25%) renal function loss after robot-assisted partial nephrectomy and identified four risk categories. We aimed to externally validate Martini’s nomogram on a large, national, multi-institutional data set including open, laparoscopic, and robot-assisted partial nephrectomy. Methods: Data of 2584 patients treated with partial nephrectomy for renal masses at 26 urological Italian centers (RECORD2 project) were collected. Renal function was assessed at baseline, on third postoperative day, and then at 6, 12, 24, and 48 months postoperatively. Multivariable models accounting for variables included in the Martini’s nomog…

laparoscopy; nephron-sparing surgery; renal cell carcinoma; renal function; robotics; Humans; Kidney; Nephrectomy; Nomograms; Kidney Neoplasms; Laparoscopy; Robotic Surgical Procedures; Roboticsroboticsrenal cell carcinomaUrologyrenal functionlaparoscopynephron-sparing surgeryKidneyNephrectomyKidney NeoplasmsNomogramsRobotic Surgical ProceduresHumansLaparoscopyrobotics.Laparoscopy; nephron-sparing surgery; renal cell carcinoma; renal function; robotics.International Journal of Urology
researchProduct

Transperitoneal vs retroperitoneal minimally invasive partial nephrectomy: comparison of perioperative outcomes and functional follow-up in a large m…

2020

Abstract Background Aim of this study was to evaluate and compare perioperative outcomes of transperitoneal (TP) and retroperitoneal (TR) approaches in a multi-institutional cohort of minimally invasive partial nephrectomy (MI-PN). Material and methods All consecutive patients undergone MI-PN for clinical T1 renal tumors at 26 Italian centers (RECORd2 project) between 01/2013 and 12/2016 were evaluated, collecting the pre-, intra-, and postoperative data. The patients were then stratified according to the surgical approach, TP or RP. A 1:1 propensity score (PS) matching was performed to obtain homogeneous cohorts, considering the age, gender, baseline eGFR, surgical indication, clinical dia…

medicine.medical_specialtyIntraoperative ComplicationUrologymedicine.medical_treatmentOperative TimeSurgical approach030232 urology & nephrologyMinimally invasive partial nephrectomy Renal cell carcinoma Retroperitoneal Surgical approach Transperitoneal.lcsh:RC870-923lcsh:RC254-282NephrectomyArticle03 medical and health sciences0302 clinical medicineRenal cell carcinomamedicineMinimally invasive partial nephrectomy; Renal cell carcinoma; Retroperitoneal; Surgical approach; TransperitonealHumansRetroperitoneal SpaceRetrospective StudiesMinimally invasive partial nephrectomybusiness.industryRenal cell carcinoma; Minimally invasive partial nephrectomy; Transperitoneal; Retroperitoneal; Surgical approachTransperitonealPerioperativeRetroperitoneallcsh:Diseases of the genitourinary system. Urologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseNephrectomyKidney NeoplasmsRenal cell carcinomaSurgerySettore MED/24Treatment Outcome030220 oncology & carcinogenesisPropensity score matchingCohortSurgeryLaparoscopyPositive Surgical MarginMinimally invasive partial nephrectomy; Renal cell carcinoma; Retroperitoneal; Surgical approach; Transperitoneal; Follow-Up Studies; Humans; Nephrectomy; Operative Time; Retroperitoneal Space; Retrospective Studies; Treatment Outcome; Kidney Neoplasms; LaparoscopybusinessAbdominal surgeryFollow-Up StudiesSurgical endoscopy
researchProduct

Predicting positive surgical margins in partial nephrectomy: A prospective multicentre observational study (the RECORd 2 project)

2020

PURPOSE: to evaluate clinical predictors of positive surgical margins (PSMs) in a large multicenter prospective observational study and to develop a clinic nomogram to predict the likelihood of PSMs after partial nephrectomy (PN). MATERIALS AND METHODS: We prospectively evaluated 4308 patients who had surgical treatment for renal tumors between January 2013 and December 2016 at 26 urological Italian Centers (RECORd 2 project). Two multivariable logistic models were evaluated to predict the likelihood of PSMs. Center caseload was dichotomized using a visual assessment adjusted for several predictors of PSMs. A nomogram predicting PSMs was developed. RESULTS: Overall, 2076 patients treated wi…

MaleNeoplasm ResidualDatabases Factualmulticenter prospective observational studymedicine.medical_treatment030232 urology & nephrologyNephron-sparing surgeryNephrectomyNomogram0302 clinical medicineRenal cell carcinomaRisk Factorsclinical predictorPartial nephrectomyProspective StudiesStage (cooking)Prospective cohort studySurgical margins Nephron-sparing surgery Nomogram Partial nephrectomy Renal cell carcinoma Robot-assisted partial nephrectomySurgical marginsRobot-assisted partial nephrectomyMargins of ExcisionGeneral MedicineMiddle AgedNephrectomyKidney NeoplasmsHospitalsRenal cell carcinomaOncologyElective Surgical Procedures030220 oncology & carcinogenesisArea Under CurveResidualNephron-sparing surgery; Nomogram; Partial nephrectomy; Renal cell carcinoma; Robot-assisted partial nephrectomy; Surgical marginsFemalepositive surgical marginPositive Surgical MarginElective Surgical Proceduremedicine.medical_specialtyHospitals Low-VolumeHigh-Volume03 medical and health sciencesDatabasesSurgical margins; Nephron-sparing surgery; Nomogram; Partial nephrectomy; Renal cell carcinoma; Robot-assisted partial nephrectomyInternal medicineLow-VolumemedicineHumansNeoplasm InvasivenessCarcinoma Renal CellFactualAgedNeoplasm Stagingbusiness.industryCarcinomaRenal CellNomogrammedicine.diseaseNomogramsSettore MED/24Logistic ModelsROC CurveNeoplasmSurgeryObservational studybusinessHospitals High-Volume
researchProduct

How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency?

2020

The COVID-19 outbreak, in a few weeks, overloaded Italian hospitals, and the majority of medical procedures were postponed. During the pandemic, with hospital reorganization, clinical and learning activities performed by residents suffered a forced remodulation. The objective of this study is to investigate how urology training in Italy has been affected during the COVID-19 era. In this multi-academic study, we compared residents' training during the highest outbreak level with their previous activity. Overall 387 (67.1%) of the 577 Italian Urology residents participated in a 72-h anonymous online survey with 36 items sent via email. The main outcomes were clinical/surgical activities, soci…

Telemedicinemedicine.medical_specialtyMultivariate analysisCoronavirus disease 2019 (COVID-19)Distance teachingDistance educationeducation030232 urology & nephrologyUrologylcsh:Surgery03 medical and health sciences0302 clinical medicineCOVID-19; pandemic; residency; residents; urologyMultidisciplinary approachPandemicMedicineresidenturologyOriginal ResearchSettore MED/24 - UROLOGIAbusiness.industrySocial distancepandemicCOVID-19lcsh:RD1-811Settore MED/24030220 oncology & carcinogenesisresidentsSurgeryurology; residency; residents; pandemic; COVID-19businessresidency
researchProduct

Epidermal Growth Factor Receptor (EGFR) Cell Expression During Adjuvant Treatment After Transurethral Resection for Non-Muscle-Invasive Bladder Cance…

2019

Abstract Background The aim of the study was to investigate the feasibility of Epidermal Growth Factor Receptor (EGFR) measurement in bladder washings of patients affected by non–muscle-invasive bladder cancer (NMIBC) and its prognostic role in identifying risk subgroups and predicting disease recurrence and progression. Patients and Methods Patients with NMIBC treated with transurethral resection of bladder tumor (TURBT) from 2012 to 2015 were enrolled. Samples of bladder washings were collected and stored at −80°C until RNA extraction. The cDNA obtained from RNA was used to perform a gene expression analysis by a real time polymerase chain reaction. Results An adequate cellular pellet was…

MaleOncologymedicine.medical_specialtyUrology030232 urology & nephrologyCystectomy03 medical and health sciences0302 clinical medicineInterquartile rangeInternal medicineAdjuvant therapyHumansMedicineEpidermal growth factor receptorAgedBladder cancerBladder washingbiologybusiness.industryHazard ratioCancerBiomarkerPrognosismedicine.diseaseConfidence intervalEpidermal Growth Factor Receptor (EGFR)Up-RegulationErbB ReceptorsGene Expression Regulation NeoplasticAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsOncologyNon-Muscle Invasive Bladder Cancer (NMIBC)Chemotherapy Adjuvant030220 oncology & carcinogenesisMolecular classificationDisease Progressionbiology.proteinFeasibility StudiesBiomarker (medicine)Femalebusiness
researchProduct

40(th) EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004

2004

0303 health sciencesmedicine.medical_specialtybusiness.industryEASDEndocrinology Diabetes and MetabolismHuman physiologymedicine.disease03 medical and health sciences0302 clinical medicineDiabetes mellitusFamily medicineInternal MedicineMedicinebusiness030217 neurology & neurosurgery030304 developmental biology
researchProduct

An experimental proposal for a Gaussian amendable quantum channel

2013

We propose a quantum optics experiment where a single two-mode Gaussian entangled state is used for realizing the paradigm of an amendable Gaussian channel recently presented in Phys. Rev. A, \textbf{87}, 062307 (2013). Depending on the choice of the experimental parameters the entanglement of the probe state is preserved or not and the relative map belongs or not to the class of entanglement breaking channels. The scheme has been optimized to be as simple as possible: it requires only a single active non-linear operation followed by four passive beam-splitters. The effects of losses, detection inefficiencies and statistical errors are also taken into account, proving the feasibility of the…

Quantum PhysicsFOS: Physical sciencesQuantum Physics (quant-ph)
researchProduct

sj-jpg-1-tau-10.1177_1756287221995683 – Supplemental material for Fibronectin urothelial gene expression as a new reliable biomarker for early detect…

2021

Supplemental material, sj-jpg-1-tau-10.1177_1756287221995683 for Fibronectin urothelial gene expression as a new reliable biomarker for early detection of local toxicity secondary to adjuvant intravesical therapy for non-muscle invasive bladder cancer by Fabrizio Di Maida, Cristina Scalici Gesolfo, Riccardo Tellini, Andrea Mari, Chiara Sanfilippo, Luca Lambertini, Antonio Andrea Grosso, Marco Carini, Andrea Minervini and Vincenzo Serretta in Therapeutic Advances in Urology

FOS: Clinical medicine111403 Paediatrics111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
researchProduct